Viral exanthema as manifestation of SARS-CoV-2 infection : A case report

RATIONALE: The clinical manifestations of the SARS-CoV-2 infection are mainly respiratory but the virus can cause a variety of symptoms. Dermatological findings are less well-characterized. Data is scarce on their timing, type and correlation with the immune response.

PATIENT CONCERNS: We present the case of SARS-CoV-2 infection in a previously healthy woman who presented with respiratory symptoms and developed anosmia, diarrhea, and an erythematous maculo-papular rash on day 15 from symptom onset.

DIAGNOSIS: The nasopharyngeal swab tested by real time PCR for COVID-19 was positive. We interpreted this as a viral exanthema likely caused by an immune response to SARS-CoV-2 nucleotides.

INTERVENTIONS: She was treated with Hydroxychloroquine, Azithromycin and Lopinavir/Ritonavir, and the rash with topical corticosteroids.

OUTCOMES: All symptoms resolved except for anosmia which persisted for 6 weeks. At the 4- and 6-weeks follow-up the IgG titers for SARS-CoV-2 were high.

LESSONS: We must consider that SARS-CoV-2 has a multi-organ tropism. In our case, the SARS-CoV-2 infection had lung, nasopharyngeal, neurological, digestive, and skin manifestations. Identifying the different manifestations is useful for understanding the extent of SARS-CoV-2 infection. We not only present a rare manifestation but also suggest that cutaneous manifestations may correlate with immunity.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:99

Enthalten in:

Medicine - 99(2020), 35 vom: 28. Aug., Seite e21810

Sprache:

Englisch

Beteiligte Personen:

Iancu, Gabriela Mariana [VerfasserIn]
Solomon, Adelaida [VerfasserIn]
Birlutiu, Victoria [VerfasserIn]

Links:

Volltext

Themen:

2494G1JF75
4QWG6N8QKH
83905-01-5
Antiviral Agents
Azithromycin
Case Reports
Drug Combinations
Glucocorticoids
Hydroxychloroquine
Journal Article
Lopinavir
Lopinavir-ritonavir drug combination
O3J8G9O825
Ritonavir

Anmerkungen:

Date Completed 08.09.2020

Date Revised 12.11.2023

published: Print

Citation Status MEDLINE

doi:

10.1097/MD.0000000000021810

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM314449000